Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Typewriter Therapeutics, Inc. emerges from stealth with $56 million in Series A financing led by AN Venture Partners and RA Capital Management to develop in vivo CAR T medicines.

PRIVATESep 02, 2026•5 days ago

Amount Raised

$56 Million

Round Type

Series A

BiotechnologyHealth CareGeneticsTherapeutics

Investors

Sbi Us Gateway FundGemsekiAnriRa Capital ManagementAn Venture Partners

Description

Typewriter Therapeutics, Inc. has raised $56 million in Series A financing to further its development of safe and durable genetic medicines. The financing was led by AN Venture Partners and RA Capital Management, with participation from ANRI, Gemseki, and SBI US Gateway Fund. The company aims to focus on in vivo CAR T and genetic liver diseases

Company Information

Company

Typewriter Therapeutics

About

Typewriter Therapeutics, Inc. is a biotech company developing safe, durable, and re-dosable genetic medicines with curative potential for patients with cancer, autoimmune diseases, and severe genetic disorders. Their innovative technology utilizes site-specific, non-viral methods to insert whole genes into the genome using LNP-delivered RNA. With a focus on in vivo CAR T and genetic liver diseases, Typewriter aims to create accessible genetic treatments for patients. The company's approach leverages the natural gene-insertion capabilities of the R2 retrotransposon.

Don't miss Typewriter Therapeutics's next move

Get an email the moment Typewriter Therapeutics raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Typewriter Therapeutics's next move

See what Strategic adds

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Typewriter Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.